

YOU'RE INVITED

to attend a clinical presentation about the efficacy and safety of VENCLEXTA regimens in the treatment of CLL



EXPLORING TIME OFF TREATMENT WITH A BCL-2 INHIBITOR*†

A Review of VENCLEXTA-Based Regimens for Patients With CLL/SLL

***VEN+G regimen:** Designed to be completed after 12 months (twelve 28-day treatment cycles): GAZYVA® (obinutuzumab) is administered in Cycles 1-6, and VENCLEXTA is taken orally 400 mg/day from Cycle 3, Day 1, after the first two cycles of GAZYVA and the 5-week VENCLEXTA dose ramp-up.¹

†**VEN+R regimen:** Designed to be completed after 24 months (twenty-four 28-day treatment cycles after the 5-week VENCLEXTA dose ramp-up): rituximab is administered in Cycles 1-6; VENCLEXTA is taken orally 400 mg/day from Cycle 1, Day 1 of rituximab through Cycle 24.¹

<Including the latest long-term follow-up data for CLL regimens, presented at EHA 2023>

VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).¹



Nadia Khan, MD

, Swedish Cancer Institute, SCI Center for Blood Disorders and Cellular Therapy



DATE/TIME

Wednesday, February 07, 2024

Program Time: 6:30 PM PT



LOCATION

Aerlume Seattle
2003 Western Avenue Suite C
Seattle, WA 98121



RSVP

By Wednesday, January 31, 2024
To Jules Holland
(253) 349-3350
jules.holland@abbvie.com

RSVP Online:

<https://rsvp.abbviespeakerprograms.com/id/189436>



Scan the QR code to register

During this program, we will

Review clinical outcomes of VENCLEXTA regimens for CLL

Discuss how to dose and administer VENCLEXTA for patients with CLL

Consider what a chance for time off treatment could mean for your patients with CLL

Select Important Safety Information¹

- Concomitant use of VENCLEXTA with *strong* CYP3A inhibitors at initiation and during ramp-up is contraindicated in patients with CLL/SLL due to the potential for increased risk of tumor lysis syndrome (TLS).
- Tumor lysis syndrome, including fatal events and renal failure requiring dialysis, has occurred in patients treated with VENCLEXTA. The risk of TLS is a continuum based on multiple factors, particularly reduced renal function, tumor burden, and type of malignancy. Assess all patients for risk and provide appropriate prophylaxis for TLS, including hydration and anti-hyperuricemics. Monitor blood chemistries and manage abnormalities promptly. Employ more intensive measures (IV hydration, frequent monitoring, hospitalization) as overall risk increases. Interrupt dosing if needed; when restarting VENCLEXTA follow dose modification guidance in the Prescribing Information.
- Concomitant use of VENCLEXTA with P-gp inhibitors or strong or moderate CYP3A inhibitors increases venetoclax exposure, which may increase the risk of TLS at initiation and during the ramp-up phase, and requires VENCLEXTA dose reduction.
- Grade 3 or 4 neutropenia occurred in patients treated with VENCLEXTA. Monitor complete blood counts and for signs of infection; manage as medically appropriate.
- Fatal and serious infections such as pneumonia and sepsis have occurred in patients with VENCLEXTA. Monitor patients for signs and symptoms of infection and treat promptly. Withhold VENCLEXTA for Grade 3 and 4 infection until resolution.
- Do not administer live attenuated vaccines prior to, during, or after treatment until B-cell recovery occurs.
- VENCLEXTA may cause embryo-fetal harm. Advise females of reproductive potential to use effective contraception during treatment and for 30 days after the last dose.

VENCLEXTA® and its design are registered trademarks of AbbVie Inc.

GAZYVA® is a registered trademark of Genentech, Inc.

BCL-2=B-cell lymphoma-2; VEN+G=VENCLEXTA + GAZYVA; VEN+R=VENCLEXTA + rituximab; IV=intravenous; P-gp=P-glycoprotein<; CME=continuing medical education>.

<Please note that this is a promotional educational program; CME credit will not be available.>

Please see additional Important Safety Information on the next page. Please see accompanying full [Prescribing Information](https://www.rxabbvie.com/pdf/venclxxta.pdf) or visit <https://www.rxabbvie.com/pdf/venclxxta.pdf>

abbvie

Important Safety Information¹

Contraindication

- Concomitant use of VENCLEXTA with *strong* CYP3A inhibitors at initiation and during ramp-up phase is contraindicated in patients with CLL/SLL due to the potential for increased risk of tumor lysis syndrome (TLS).

Tumor Lysis Syndrome

- Tumor lysis syndrome, including fatal events and renal failure requiring dialysis, has occurred in patients treated with VENCLEXTA.
- VENCLEXTA can cause rapid reduction in tumor and thus poses a risk for TLS at initiation and during the ramp-up phase in all patients, and during reinitiation after dosage interruption in patients with CLL/SLL. Changes in blood chemistries consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of VENCLEXTA and at each dose increase. TLS, including fatal cases, has been reported after a single 20 mg dose.
- In patients with CLL/SLL who followed the current (5 week) dose ramp-up and the TLS prophylaxis and monitoring measures, the rate of TLS was 2% in the VENCLEXTA CLL/SLL monotherapy trials. The rate of TLS remained consistent with VENCLEXTA in combination with obinutuzumab or rituximab. With a 2- to 3-week dose ramp-up and higher starting dose in patients with CLL/SLL, the TLS rate was 13% and included deaths and renal failure.
- The risk of TLS is a continuum based on multiple factors, particularly reduced renal function, tumor burden, and type of malignancy. Splenomegaly may also increase the risk of TLS in patients with CLL/SLL.
- Assess all patients for risk and provide appropriate prophylaxis for TLS, including hydration and anti-hyperuricemics. Monitor blood chemistries and manage abnormalities promptly. Employ more intensive measures (IV hydration, frequent monitoring, hospitalization) as overall risk increases. Interrupt dosing if needed; when restarting VENCLEXTA follow dose modification guidance in the Prescribing Information.
- Concomitant use of VENCLEXTA with P-gp inhibitors or strong or moderate CYP3A inhibitors increases venetoclax exposure, which may increase the risk of TLS at initiation and during the ramp-up phase, and requires VENCLEXTA dose reduction.

Neutropenia

- In patients with CLL, Grade 3 or 4 neutropenia developed in 63% to 64% of patients and Grade 4 neutropenia developed in 31% to 33% of patients when treated with VENCLEXTA in combination and monotherapy studies. Febrile neutropenia occurred in 4% to 6% of patients.
- Monitor complete blood counts. Interrupt dosing for severe neutropenia and resume at same or reduced dose. Consider supportive measures including antimicrobials and growth factors (e.g., G-CSF).

Infections

- Fatal and serious infections such as pneumonia and sepsis have occurred in patients treated with VENCLEXTA. Monitor patients for signs and symptoms of infection and treat promptly. Withhold VENCLEXTA for Grade 3 and 4 infection until resolution and resume at same or reduced dose.

Immunization

- Do not administer live attenuated vaccines prior to, during, or after treatment with VENCLEXTA until B-cell recovery occurs. Advise patients that vaccinations may be less effective.

Embryo-Fetal Toxicity

- VENCLEXTA may cause embryo-fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment and for 30 days after the last dose.

Increased Mortality in Patients with Multiple Myeloma when VENCLEXTA is Added to Bortezomib and Dexamethasone

- In a randomized trial (BELLINI; NCT02755597) in patients with relapsed or refractory multiple myeloma, the addition of VENCLEXTA to bortezomib plus dexamethasone, a use for which VENCLEXTA is

not indicated, resulted in increased mortality. Treatment of patients with multiple myeloma with VENCLEXTA in combination with bortezomib plus dexamethasone is not recommended outside of controlled clinical trials.

Adverse Reactions

- In patients with CLL receiving combination therapy with obinutuzumab**, serious adverse reactions were most often due to febrile neutropenia and pneumonia (5% each). The most common adverse reactions ($\geq 20\%$) of any grade were neutropenia (60%), diarrhea (28%), and fatigue (21%). Fatal adverse reactions that occurred in the absence of disease progression and with onset within 28 days of the last study treatment were reported in 2% (4/212) of patients, most often from infection.
- In patients with CLL receiving combination therapy with rituximab**, the most frequent serious adverse reaction ($\geq 5\%$) was pneumonia (9%). The most common adverse reactions ($\geq 20\%$) of any grade were neutropenia (65%), diarrhea (40%), upper respiratory tract infection (39%), fatigue (22%), and nausea (21%). Fatal adverse reactions that occurred in the absence of disease progression and within 30 days of the last VENCLEXTA treatment and/or 90 days of the last rituximab were reported in 2% (4/194) of patients.
- In patients with CLL/SLL receiving monotherapy**, the most frequent serious adverse reactions ($\geq 5\%$) were pneumonia (9%), febrile neutropenia (5%), and sepsis (5%). The most common adverse reactions ($\geq 20\%$) of any grade were neutropenia (50%), diarrhea (43%), nausea (42%), upper respiratory tract infection (36%), anemia (33%), fatigue (32%), thrombocytopenia (29%), musculoskeletal pain (29%), edema (22%), and cough (22%). Fatal adverse reactions that occurred in the absence of disease progression and within 30 days of venetoclax treatment were reported in 2% of patients in the VENCLEXTA monotherapy studies, most often (2 patients) from septic shock.

Drug Interactions

- Concomitant use with a P-gp inhibitor or a strong or moderate CYP3A inhibitor increases VENCLEXTA exposure, which may increase VENCLEXTA toxicities, including the risk of TLS. Consider alternative medications or adjust VENCLEXTA dosage and monitor more frequently for adverse reactions. Resume the VENCLEXTA dosage that was used prior to concomitant use of a P-gp inhibitor or a strong or moderate CYP3A inhibitor 2 to 3 days after discontinuation of the inhibitor.
- Patients should avoid grapefruit products, Seville oranges, and starfruit during treatment as they contain inhibitors of CYP3A.
- Avoid concomitant use of strong or moderate CYP3A inducers.
- Monitor international normalized ratio (INR) more frequently in patients receiving warfarin.
- Avoid concomitant use of VENCLEXTA with a P-gp substrate. If concomitant use is unavoidable, separate dosing of the P-gp substrate at least 6 hours before VENCLEXTA.

Lactation

- Advise women not to breastfeed during treatment with VENCLEXTA and for 1 week after the last dose.

Females and Males of Reproductive Potential

- Advise females of reproductive potential to use effective contraception during treatment with VENCLEXTA and for 30 days after the last dose.
- Based on findings in animals, VENCLEXTA may impair male fertility.

Hepatic Impairment

- Reduce the dose of VENCLEXTA for patients with severe hepatic impairment (Child-Pugh C); monitor these patients more frequently for adverse reactions. No dose adjustment is recommended for patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment.

G-CSF=granulocyte-colony stimulating factor.

Please see accompanying full [Prescribing Information](#) or visit <https://www.rxabbvie.com/pdf/venclax.pdf>

Reference: 1. VENCLEXTA Prescribing Information.

AbbVie is committed to collaborating with healthcare professionals (HCPs), healthcare organizations (HCOs), and patient organizations to improve patient health across the globe. Our interactions with HCPs, HCOs, and patient organizations are guided by openness and transparency to ensure public trust and confidence. AbbVie supports disclosure of these relationships wherever possible to demonstrate the integrity of our relationships with HCPs, HCOs, and patient organizations.

AbbVie reports payment and transfer of value data as required by federal and state transparency laws. Additional information regarding AbbVie's HCP and HCO transparency reporting is available on the www.abbvie.com website. If you have any questions, please speak to your AbbVie contact or email TransparencyReporting@abbvie.com.

© 2023 AbbVie. All rights reserved. | US-VENC-230287 | November 2023 | Program ID 189436



abbvie